Cognitive function changes with risperidone monotherapy and their relationship to psychotic symptoms in treatment-na?ve first-episode schizophrenia patients

胡茂林,宗小芬,唐劲松,廖艳辉,李宗昌,贺莹,陈晓岗

DOI: https://doi.org/10.13479/j.cnki.jip.2018.04.004

2018-01-01

Abstract:Objective To explore cognitive function changes after risperidone monotherapy and their relationship to psychotic symptoms in treatment-na?ve first-episode schizophrenia patients. Methods We collected 42 treatmentna?ve patients with first-episode schizophrenia, and used Wisconsin Card Sorting Test (WCST), Digit Span Distraction Test (DSDT), Verbal Fluency Test (VFT), Stroop Color Word Test and Trail Marking Test (TMT) to explore their executive function, working memory and information processing speed. Positive and Negative Syndrome Scale (PANSS) was used to evaluate patients' symptoms at baseline and after treatment. Multiple regression analysis was utilized to compute the relation between cognitive deficits and symptoms. Results At baseline, WCST_perseverative errors of patients were significantly more than controls (P<0.001);the number of WCST_categories, DSDT_forward/backward and VFT was significantly less than controls (Ps<0.01). The time consumed in Stroop and TMT of patients was significantly more than that of controls (Ps<0.001). After treatment, patients' time consumed in Stroop_B and Stroop_C was significantly less than that at baseline, but there were no significant within-group differences in other cognitive performance. The worse of the performance in TMT_A/B, the more severe of patients' negative and total symptoms (Ps<0.05). The worse performance of the TMT_A at baseline, the less improvement of patients' positive symptoms (P=0.019). Conclusions Patients already have suffered from extensive cognitive impairments in their early episode. Patients' psychotic symptoms and information processing deficits can be improved after therapy, although their executive function and working memory are not improved. These imply that information processing deficits in patients may be state-biomarkers, but executive function and working memory impairments may be trait-biomarkers.